Quality of life independently predicts overall survival in myelofibrosis: Key insights from the COntrolled MyeloFibrosis Study with ORal Janus kinase inhibitor Treatment (COMFORT)-I study

Heidi E. Kosiorek, Robyn M. Scherber, Holly L. Geyer, Srdan Verstovsek, Blake T. Langlais, Gina L. Mazza, Jason Gotlib, Vikas Gupta, Leslie J. Padrnos, Jeanne M. Palmer, Angela Fleischman, Ruben A. Mesa, Amylou C. Dueck

Research output: Contribution to journalLetterpeer-review

Original languageEnglish (US)
JournalBritish journal of haematology
StateAccepted/In press - 2022


  • myelofibrosis
  • prognostic factors
  • quality of life
  • survival

ASJC Scopus subject areas

  • Hematology

Cite this